12:06 PM EST - ProMIS Neurosciences Inc : Announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration (FDA) for PMN310 for the treatment of Alzheimer’s disease. ProMIS Neurosciences Inc
shares T.PMN are trading unchanged at $6.75.
